Introduction#
Adial Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has submitted an application for its drug AD04 to the FDA’s Commissioner’s National Priority Voucher Pilot Program. This program aims to speed up the review process for drugs that address significant U.S. health priorities.
What is the CNPV Program?#
The Commissioner’s National Priority Voucher (CNPV) program, introduced in 2025, is designed to shorten the FDA review timeline for certain drugs. Typically, drug reviews can take 10 to 12 months, but under this program, the timeline could be reduced to just one to two months after all necessary materials are submitted. This initiative allows for more direct communication between companies and the FDA, facilitating a rolling review process. Notably, the vouchers awarded through this program cannot be sold or transferred to other companies.
About AD04#
AD04 is a medication aimed at treating Alcohol Use Disorder, specifically for patients who drink heavily. It works as a serotonin-3 receptor antagonist, targeting specific genetic profiles identified through Adial’s proprietary genetic testing. Cary Claiborne, the company’s CEO, emphasized that being part of this program could significantly accelerate the FDA review process for AD04.
Recent Developments#
Adial is preparing for a new Phase 3 clinical trial for AD04, following promising results from its previous ONWARD trial, which indicated the drug could help reduce drinking without major safety concerns. Additionally, the company has successfully produced a demonstration batch of AD04 that meets the specifications for the upcoming trial. Adial has also entered into a framework agreement with Molteni Farmaceutici to explore an exclusive partnership for commercializing AD04 in Europe. Furthermore, recent FDA policy changes may allow Adial to seek approval with only one pivotal clinical trial, potentially streamlining the approval process for AD04.